Report of Foreign Issuer (6-k)
20 May 2016 - 11:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 20, 2016
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
FDA
posts briefing materials prior to Advisory Committee meeting for IDegLira, a fixed combination product of insulin degludec and
liraglutide
Bagsværd, Denmark, 20 May 2016 –
Novo Nordisk announced
today that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the 24 May 2016 Advisory Committee
meeting to discuss the New Drug Application (NDA) for IDegLira, the fixed combination product of insulin degludec (Tresiba
®
)
and liraglutide (Victoza
®
).
The briefing documents from Novo Nordisk and the FDA,
which will form the basis for the Advisory Committee’s discussion, provide an overview of the non-clinical and clinical data
for IDegLira for the treatment of type 2 diabetes.
The briefing materials can be accessed on the FDA webpage:
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrinol
ogicandMetabolicDrugsAdvisoryCommittee/ucm491062.htm
About advisory committee meetings
FDA advisory committees are panels of independent experts who advise
the FDA on specific questions raised by the FDA as they consider regulatory decisions. The FDA is not bound by the committee's
recommendation, but it takes its advice into consideration when reviewing a new drug application. According to the FDA Amendment
Act of 2007 (FDAAA), the FDA should refer new drugs to an advisory committee meeting, or alternatively justify why an advisory
committee meeting was not requested.
About IDegLira
IDegLira is a once-daily, single injection combination product consisting
of insulin degludec (Tresiba
®
), a once-daily new-generation basal insulin analogue, and
liraglutide (Victoza
®
), a once-daily GLP-1 analogue.
IDegLira
was submitted to the FDA in September 2015 under the US FDA's Prescription Drug User Fee Act V (PDUFA V) regulation. In Europe,
IDegLira was approved in September 2014 and is marketed under the brand name Xultophy
®
.
Page 2 of 2
Novo Nordisk is a global healthcare company with more
than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also
enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in
Denmark, Novo Nordisk employs approximately 41,600 people in 75 countries and markets its products in more than 180 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For
more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information
Media:
|
Katrine Sperling
|
+45 3079 6718
|
krsp@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 786 8316
|
kiau@novonordisk.com
|
|
|
|
Investors:
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Melanie Raouzeos
|
+45 3075 3479
|
mrz@novonordisk.com
|
Kasper Veje (US)
|
+1 609 235 8567
|
kpvj@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 41 / 2016
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: May 20, 2016
|
NOVO NORDISK A/S
Lars Rebien Sørensen,
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From May 2023 to May 2024